Matrix Laboratories Ltd
Matrix Laboratories Ltd
Pai R.,Matrix Laboratories Ltd |
Kohli K.,Matrix Laboratories Ltd
International Journal of Drug Delivery | Year: 2011
The study involves a newer approach of compression of matrix pellets into disintegrating tablet to overcome the rupture of polymer coat during compression of reservoir type pellets. Matrix pellets containing Sodium alginate (Kelton LV CR) at a level of 10, 20 and 30 %w/w was prepared by extrusion/spheronization technique. Sertraline hydrochloride was used as model drug and in vitro release profile of 12 h was targeted. Calcium chloride was used either by granulating the sodium alginate containing blend with 10% w/w solution or by pouring the wet pellets into saturated solution of calcium chloride. Tablets containing pellets were prepared by direct compression process. Acceptance value was used employed to evaluate the uniformity of drug content. In vitro drug release from alginate containing pellets was complete within 4 h and the desired release profile could be achieved only from pellets treated with calcium chloride. The drug release from the uncompressed pellet and compressed tablet was identical, as each pellet was behaving like a monolithic mini matrix system. Scanning electron micrographs of the tablet indicated the uniform distribution of the pellets within the diluent blend. Scanning electron micrographs of the pellets obtained after completion the dissolution test were found to be left with empty sac like structure releasing the drug indicating anomalous type drug release. Matrix pellets containing sodium alginate could be prepared by extrusion spheronization technique which can be an alternative approach in preparing disintegrating tablets from pellets.
Mehatha A.K.,Matrix Laboratories Ltd |
Suryadevara V.,Matrix Laboratories Ltd |
Lankapalli S.R.,Matrix Laboratories Ltd |
Deshmukh A.M.,Matrix Laboratories Ltd |
Sambath L.P.,Matrix Laboratories Ltd
Turkish Journal of Pharmaceutical Sciences | Year: 2014
The solubility behaviour of drugs remains one of the most challenging aspects in formulation development. Many different methods have been tried over a long period for enhancing the solubility of poorly soluble drugs. Preparing a solid dispersion is one among the methods. Solid dispersions in water-soluble carriers have shown promising results as a means of enhancing the dissolution rate, thus improving bioavailability for most of hydrophobic drugs. The objective of the present study was to enhance the solubility and dissolution rate of a poorly water-soluble drug, ezetimibe. Solid dispersions were prepared by using Kollidon VA64 as carrier with different drug-to-carrier ratios. Dispersions with Kollidon VA64 were prepared by melt extrusion technique. These formulations were characterized for solid state properties by differential scanning calorimetry, X-ray powder diffraction and FTIR spectral studies. Formulations were further evaluated for dissolution and stability studies. The aqueous solubility of ezetimibe, in present formulations was improved by the presence of polymer. Solid-state characterization indicated that ezetimibe was present as amorphous material in formulation with kollidon VA64, due to efficient entrapment in polyer matrix. Ezetimibe in pure form has very slow dissolution rate, when compared with dispersions.